Insider Trading Activity For Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
David Domzalski , CEO of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) reportedly Sold 602 shares of the company’s stock at an average price of 5.08 for a total transaction amount of $3,058.16 SEC Form
Insider Trading History For Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
On 1/2/2018 Meir Eini, Insider, sold 5,000 with an average share price of $6.18 per share and the total transaction amounting to $30,900.00.
On 1/4/2018 Meir Eini, Insider, sold 5,000 with an average share price of $6.68 per share and the total transaction amounting to $33,400.00.
On 1/8/2018 Meir Eini, Insider, sold 5,000 with an average share price of $6.17 per share and the total transaction amounting to $30,850.00.
On 1/10/2018 Meir Eini, Insider, sold 5,000 with an average share price of $6.05 per share and the total transaction amounting to $30,250.00.
On 3/1/2018 David Domzalski, CEO, sold 66 with an average share price of $5.95 per share and the total transaction amounting to $392.70.
On 3/2/2018 Russell P Elliott, VP, sold 817 with an average share price of $6.14 per share and the total transaction amounting to $5,016.38.
On 4/2/2018 Russell P Elliott, VP, sold 142 with an average share price of $5.08 per share and the total transaction amounting to $721.36.
Analyst Ratings History For Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
- On 7/19/2017 Credit Suisse Group Reiterated Rating Buy with a price target of $9.00
- On 12/14/2017 Guggenheim Reiterated Rating Buy with a price target of $8.00
- On 1/5/2018 HC Wainwright Set Price Target of rating Buy with a price target of $12.00
Recent Trading Activity for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Shares of Foamix Pharmaceuticals Ltd closed the previous trading session at 4.98 +0.00 0.00% with 5.0 shares trading hands.